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Abstract Psoriatic arthritis (PsA) is a chronic, systemic
inflammatory disease. Up to 40 % of patients with psoriasis
will go on to develop PsA, usually within 5–10 years of
cutaneous disease onset. Both conditions share common
pathogenic mechanisms involving genetic and environ-
mental factors. Because psoriasis is typically present for
years before PsA-related joint symptoms emerge, derma-
tologists are in a unique position to detect PsA earlier in the
disease process through regular, routine screening of pso-
riasis patients. Distinguishing clinical features of PsA
include co-occurrence of psoriatic skin lesions and nail
dystrophy, as well as dactylitis and enthesitis. Patients with
PsA are usually seronegative for rheumatoid factor, and
radiographs may reveal unique features such as juxta-
articular new bone formation and pencil-in-cup deformity.
Early treatment of PsA with disease-modifying anti-rheu-
matic drugs has the potential to slow disease progression
and maintain patient quality of life. Optimally, a single
therapeutic agent will control both the skin and joint pso-
riatic symptoms. A number of traditional treatments used to
manage psoriasis, such as methotrexate and cyclosporine,
are also effective for PsA, but these agents are often
inadequately effective, temporary in benefit and associated
with significant safety concerns. Biologic anti-tumour
necrosis factor agents, such as etanercept, infliximab and
adalimumab, are effective for treating patients who have
both psoriasis and PsA. However, a substantial number of
patients may lose efficacy, have adverse effects or find
intravenous or subcutaneous administration inconvenient.
Emerging oral treatments, including phosphodiesterase 4
inhibitors, such as apremilast, and new biologics targeting
interleukin-17, such as secukinumab, brodalumab and ix-
ekizumab, have shown encouraging clinical results in the
treatment of psoriasis and/or PsA. Active and regular col-
laboration of dermatologists with rheumatologists in man-
aging patients who have psoriasis and PsA is likely to yield
more optimal control of psoriatic dermal and joint symp-
toms, and improve long-term patient outcomes.
1 Introduction
Psoriasis is a chronic, inflammatory systemic disease typ-
ically characterized by erythematous, scaly patches, or
plaques on the skin resulting from hyperproliferation of
epidermal keratinocytes [1, 2]. The disorder affects
approximately 1–3 % of the world population [3–6]. Pso-
riatic arthritis (PsA) is a spondyloarthritic condition, which
is present in up to 42 % of individuals with psoriasis and
has an estimated prevalence of 0.1–1.0 % in the general
population [7]. PsA is characterized by synovitis, enthesi-
tis, dactylitis and spondylitis [8, 9]. Psoriasis and PsA share
common pathophysiologic mechanisms (Fig. 1) [10–14];
nearly all individuals with PsA also have psoriasis [10].
Between 6 and 42 % of patients with psoriasis will
develop PsA [8], although lower estimates may reflect a
missed diagnosis or misdiagnosis [7, 15, 16]. In a study that
assessed the prevalence and clinical pattern of PsA in 1,511
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patients with psoriasis, 312 (21 %) had existing PsA and
85 % of these cases had been diagnosed for the first time
during the study [17]. In a more recent study, 949 psoriasis
patients seen serially in dermatology clinics were subse-
quently evaluated by rheumatologists; 30 % were diag-
nosed with PsA and 41 % of these had not been aware of
the diagnosis [18]. PsA is often undiagnosed or misdiag-
nosed. Skin disease generally precedes joint disease in the
majority (&75–80 %) of patients, with a typical lag time
of about 7–12 years from the onset of psoriasis to diagnosis
of PsA [3, 7, 15, 19]. Thus, routinely screening psoriasis
patients for PsA in the dermatology clinic is important, as
most patients with PsA will present to a dermatologist first,
long before joint symptoms emerge. However, in 10–15 %
of cases, PsA may precede psoriasis [10].
Patients with psoriasis, PsA or both generally have
reduced health-related quality of life (QOL), productivity
and functionality similar to those of patients with other
serious diseases, such as cancer, heart disease and diabetes
[20–30]. In addition, PsA has been associated with long-
term work disability, loss of productivity and work
absenteeism [24–27]. The burden of illness associated with
PsA in patients with psoriasis has been reviewed [31, 32].
Individuals with both psoriasis and PsA may experience
emotional distress and discomfort caused by skin
involvement and pain, and physical limitations caused by
joint involvement, which could synergistically affect their
QOL [17, 33, 34]. Compared with psoriasis patients who
do not have PsA, psoriasis patients with PsA have greater
QOL impairment, including physical and mental compo-
nents of the 36-Item Short Form Health Survey [32, 34]. In
addition, patients may have difficulty determining the
appropriate provider for diagnosis and management of their
PsA, and patients may lack understanding regarding their
treatment options. Because most patients will be treated
first for the skin lesions associated with psoriasis, derma-
tologists are in a unique position to screen for and diagnose
early PsA [3, 35, 36].
2 Pathophysiology
2.1 Genetic Variations in Psoriasis and PsA
About 40 years ago, Moll and Wright reported that first-
degree relatives of individuals with PsA had a 19-fold
increase in psoriasis prevalence compared with the general
population [37]. Investigations into the genetic basis of
psoriasis and PsA have revealed commonalities as well as
distinctions between the two disease processes. Consider-
able overlap exists in human leukocyte antigens (HLAs)
associated with both diseases (e.g. B13, B17, B57, Cw6
and DR7) [10, 38]. The tumour necrosis factor (TNF)-a
locus, TNF-238, and the NOD2/PSORAS1 locus on chro-
mosome 16q, which corresponds to a variant in the
CARD15 domain previously shown to increase suscepti-
bility to Crohn’s disease, have been identified as regions







• 1:1 (male:female) prevalence 
[10] 
• Family or personal history of 
plaque psoriasis [10] 
• Cellular pathway: T cells, 
pDCs [10] 
• Transcription factors:
Decreased AP-1 [10] 
• Genetic susceptibility loci: 
CARD15/PSORAS1/NOD2, 
TNF gene polymorphism [10] 
• Cytokine and other 
mediators: TNF- , type 1 IFN, 
amphiregulin [10] 
• Estimated US prevalence: 
0.25% [10] 
• 90% of patients have skin  
lesions [10] 
• 80% have nail changes [10] 
• Transcription factors:
NF- B NF- B or MAPK [14] 
• Genetic susceptibility loci: 
HLA-B alleles (B*27 and  
B*39:01 [11] 
• Cytokine and other mediators: 
IL-12/IL-23 [10] 
• Inflammatory and cartilage 
biomarkers: hsCRP, OPG, 
MMP-3, and the CPII:C2C     
ratio [12]; RANK-positive 
perivascular mononuclear cells, 
osteoclast precursors [13] 
• Estimated US prevalence:
1% 2% [10] 
• 5% 40% of patients have 
joint lesions [10] 
• 35% 70% of patients have 
nail changes [10]   
• Transcription factors:
TNF- NF- B or MAPK [11] 
• Genetic susceptibility loci:
HLA-C alleles [11] 
• Cytokine and other 
mediators: IL-12B/IL-23r 
[10] 
Fig. 1 Shared attributes of cutaneous psoriasis and psoriatic arthritis
[10–14]. AP activator protein, CPII C-propeptide of type II collagen,
C2C collagen fragment neoepitopes Col2-3/4Clong mono, HLA human
leukocyte antigen, hsCRP highly sensitive C-reactive protein, IFN
interferon, IL interleukin, IL-12B interleukin 12 beta, IL-23r
interleukin 23 receptor, MAPK mitogen-activated protein kinase,
MMP matrix metalloproteinase, NF nuclear factor, OPG osteopro-
tegerin, pDC precursor dendritic cell, RANK receptor activator of NF-
jB, TNF tumour necrosis factor
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39–41], although findings have been inconclusive [42].
Interleukin (IL)-12 beta and IL-23 receptor are also asso-
ciated with both psoriasis and PsA [38, 43–45]. Although
the evidence is preliminary and research is ongoing, certain
single-nucleotide polymorphisms have been related to PsA
and clinical subphenotypes [46, 47]. In one such study,
Jadon and colleagues [46] detected a strong predictive
relationship between an IL-12 beta variant and the presence
of PsA; they also detected a trend towards a relationship
between an IL-23 receptor variant and erosive peripheral
joint disease.
Genetic differences between psoriasis and PsA are also
being identified. A recent study showed that psoriasis is
more closely associated with HLA-C alleles and PsA is
more closely associated with HLA-B alleles, including
HLA B*27 and B*39 [11, 48]. PSORS1 on chromosome 6p
and PSORS2 on chromosome 17q have been confirmed as
loci for genetic susceptibility to psoriasis [10]. However,
these loci have not shown a reproducible association with
PsA [10, 49]. Mapping of the major histocompatibility
complex has identified several novel loci for PsA that are
independent of known HLA susceptibility alleles [50]. A
recent study found that the frequency of C*06:02 was
lower in patients with PsA (28.7 %) than in those with
psoriasis (57.5 %) [11]. Two separate clinical patterns of
major histocompatibility complex effect have been identi-
fied; C*06 was associated with more penetrant skin disease
and less prevalent musculoskeletal disease, while an HLA-
B (B*27) phenotype was associated with more prevalent
musculoskeletal disease [11]. Together, the available evi-
dence shows that the genetic aetiology of psoriasis and PsA
is complex and appears to be based on multiple shared and
unshared genetic factors as well as environmental stimuli
[10, 51].
2.2 Inflammatory Processes and Mediators in Psoriasis
and PsA
Psoriasis and PsA show significant similarities in inflam-
matory processes and mediators. The immune system is
normally homeostatic, with mechanisms in place to turn off
an immune response and avoid tissue damage associated
with chronic inflammation [52]. Cyclic adenosine mono-
phosphate (cAMP), a naturally occurring secondary mes-
senger, helps maintain homeostasis by modulating the
network of pro-inflammatory and anti-inflammatory
mediators [53]. cAMP levels are regulated by phosphodi-
esterases (PDEs), intracellular enzymes that convert cAMP
to AMP [53]. In immune cells, PDE4 is the predominantly
active PDE [54]. The conversion of cAMP to AMP leads to
increased pro-inflammatory mediator production and
decreased anti-inflammatory mediator production [53].
Increased levels of pro-inflammatory mediators are found
in psoriatic lesions and the synovium of patients with PsA
[55–61].
Pro-inflammatory mediators that drive psoriasis and PsA
are released by a variety of cell types, including innate
immune cells, adaptive immune cells and resident immune
cells (Fig. 2) [1, 57]. Plasmacytoid dendritic cells act as
regulators of innate and active immune responses and play
a pivotal role in T cell-mediated immune responses [1, 62,
63]. Large numbers of plasmacytoid dendritic cells are
found in psoriatic skin and psoriatic synovium [10]. Acti-
vated dendritic cells present antigens and produce inter-
feron (IFN)-a and pro-inflammatory mediators, such as IL-
12 and IL-23 [1]. T cells respond to antigen presented by
myeloid dendritic cells by proliferating and differentiating
into type 1 and type 17 T helper cells, which increase the
secretion of inflammatory cytokines [1]. In one study,
messenger RNA (mRNA) levels of the T cell regulatory
cytokine IL-7, which stimulates production of pro-inflam-
matory cytokines, were increased in the synovial fluid of
patients with spondyloarthritis [64]. CD11? dendritic cells
express nitric oxide synthase and TNF-a [65], and CD8?
and CD4? T cells produce IFN-c, TNF-a and IL-2 [66].
Activated dendritic cells and associated inflammatory
signalling molecules also exert effects on other cell types,
including keratinocytes, leukocytes, neutrophils, endothe-
lial cells and vascular smooth muscle cells, marked by
chemotaxis, proliferation and production of additional
inflammatory mediators [63]. Chronic disruptions in
inflammatory signalling are believed to lead to lasting
changes in resident cells of the skin and joints, which
underlie the clinical hallmarks of psoriatic disease [1, 67].
Angiogenesis is another common but less often recognized
feature of both psoriasis and PsA [8, 68]. Angiogenic
markers, such as vascular endothelial growth factor
(VEGF), placental growth factor, VEGF receptor 2 and
neuropilin-1, are increased in psoriatic disease [67].
Chronic inflammatory signalling also plays a role in pso-
riatic joint disease. Circulating levels of Dikkopf-1 and
macrophage colony stimulating factor, both soluble medi-
ators of bone remodelling, have been found to be higher in
PsA patients than in psoriasis patients and healthy controls;
levels of these mediators have been correlated with radio-
graphic progression [69].
3 Clinical Features of PsA and Screening
Dermatologists play an important role in screening and
diagnosing patients with early PsA. Active monitoring of
psoriasis patients for signs of joint or arthritic involvement
and familiarity with PsA screening, diagnosis and treat-
ment options can help dermatologists positively impact the
clinical course of psoriatic disease [3, 8, 35, 36].
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Irreversible joint damage and PsA progression begin within
the first 2 years after disease onset, with an increase in the
number of joints affected over time; thus, routine screening
in the dermatology clinic can be key to early detection [8,
36, 70–72]. Early intervention in the PsA disease process
can inhibit or delay structural joint damage, and patients
are more likely to experience improvements in pain, fati-
gue, depression and QOL [8, 35, 72].
Because the symptoms of PsA may overlap with those
of many other inflammatory and rheumatologic conditions,
including osteoarthritis, rheumatoid arthritis (RA) and
other spondyloarthritic conditions [36], PsA is often mis-
diagnosed (Table 1) [8, 73–81]. Alternatively, a patient
may not consider it relevant or appropriate to mention
musculoskeletal symptoms to a dermatologist and may
assume that the symptoms will resolve or that there is
nothing to be done for them, thus leading to inattention.
PsA diagnosis is further complicated by the broad range of
potential musculoskeletal symptoms and an often waxing-
and-waning clinical course [8]. To identify patients who
may have PsA, dermatologists can routinely ask psoriasis
patients about key signs/symptoms of PsA, including
whether they have experienced morning stiffness in joints
lasting longer than 30 min, swelling in a finger or toe, or
nail changes. A number of screening tools have been
developed for diagnosis of PsA (Table 2) [82–88], several
of which show good sensitivity or specificity in the setting
of dermatology clinics or general medical clinics. If PsA is
suspected, referral to a rheumatologist should be consid-
ered, depending on the dermatologist’s comfort level with
managing PsA [8, 15, 89].
4 Patient Assessment, Staging and Treatment Plan
4.1 Assessment and Staging
Patients in whom there is a strong suspicion of PsA, based on
clinical presentation of arthritis, enthesitis, dactylitis and/or
spondylitis (pain, swelling, tenderness, stiffness), should
undergo a more thorough examination. The Classification
Criteria for Psoriatic Arthritis (CASPAR) [Table 3] were
developed as classification criteria for the purpose of iden-
tifying standardized groups of PsA subjects for research
where specificity is most important—not as individual
diagnostic criteria, wherein sensitivity is paramount [90].
Nonetheless, clinicians may find utility in applying the ele-
ments of CASPAR when considering a diagnosis of PsA.
CASPAR bases diagnosis on clinical presentation, history
and radiographic and laboratory evidence, and exhibits 99 %
specificity for classification of PsA [75, 90]. The stem of the
criteria requires clinician judgment that the patient has
inflammatory arthritis, enthesitis and/or spondylitis; if this
stem is fulfilled, then the other elements of the criteria can be
applied. Inflammatory features of PsA include stiffness,
pain, swelling and tenderness of the joints, ligament and
tendon insertions into bone (enthesitis), and spine, and
dactylitis (swelling of an entire digit). The severity and
pattern (e.g. symmetrical versus asymmetrical, monoartic-
ular versus polyarticular) of peripheral and axial joint dis-
ease vary widely among patients [8]. Enthesitis may be one
of the earliest signs of PsA [91]. Dactylitis occurs in up to
50 % of patients with PsA and is a marker for disease pro-
gression [92]. Spondylitis, characterized by inflammation in
Fig. 2 Mechanisms of
systemic, chronic inflammation
in psoriasis and psoriatic
arthritis. From Nestle et al. [1].
Copyright  2009,
Massachusetts Medical Society.
Reprinted with permission from
Massachusetts Medical Society.
CCL chemokine (C-C motif)
ligand, CXCL chemokine (C-X-
C motif) ligand, Th T helper,
TNF tumour necrosis factor
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joints, entheses and bones of the spine and sacroiliac joints,
may occur in a significant proportion of PsA patients [91].
PsA is characterized by joint erosions, joint space narrowing,
bony proliferation, osteolysis (e.g. pencil-in-cup deformity),
acro-osteolysis, ankylosis, spur formation and spondylitis on
radiographs [8, 90, 93]. PsA patients are typically seroneg-
ative for rheumatoid factor [10, 74, 90, 94].
Controversy exists as to whether psoriatic nail involve-
ment is predictive of PsA. Approximately 45 % of
psoriasis patients have characteristic psoriatic nail pitting,
onycholysis and hyperkeratosis but do not have concurrent
PsA [7]. Nevertheless, nail dystrophy appears to be a
clinically valuable marker that should raise suspicion of
psoriatic joint disease. In a cohort study of 1,593 patients
with psoriasis, nail dystrophy was a significant predictor of
co-existing PsA (hazard ratio 2.93, 95 % confidence
interval 1.68–5.12) [95]. Nail involvement can also help
distinguish between PsA and RA, a condition where nail
Table 1 Differential diagnosis of psoriatic arthritis (PsA) versus other rheumatic disease conditions [8, 73–81]
Clinical feature PsA Osteoarthritis Fibromyalgia Gout Ankylosing spondylitis
Psoriasis ? - - - -
Nail dystrophy ? - - - -
Enthesitis ? - ? ? Less often
Dactylitis ? - - ? Less often
Peripheral joint ? ? ? ? -
Axial joint/spondylitis ? - ? ?, less often ?
Stiffness ? ?, with mobility ? ? ?
Rheumatoid factor positivea - - - - -
a The diagnostic utility of rheumatoid factor alone is limited because a proportion of healthy individuals can be rheumatoid factor positive and,
infrequently, rheumatoid factor can be positive in patients with PsA. Therefore, detection of rheumatoid factor should not be used alone in
diagnosis of these conditions but used in conjunction with other clinical and assessment factors [73, 74, 90, 201]
Table 2 Psoriatic arthritis (PsA) screening tools
Name Overview Comments
Current tools









5 items ? joint diagram
Maximum score: NA




11 items ? pictures/diagram
Maximum score: NA
Threshold score = 8
Sensitivity 86.8 %
Specificity 93.1 %




ePASQ [87] 10 items ? joint diagram
Self-report
Exact match of paper version






EARP Early Arthritis for Psoriatic Patients, ePASQ Electronic Psoriatic Arthritis Screening Questionnaire, NA not applicable, PASE Psoriatic
Arthritis Screening and Evaluation, PASQ Psoriatic Arthritis Screening Questionnaire, PEST Psoriasis Epidemiology Screening Tool, ToPAS
Toronto Psoriatic Arthritis Screening
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dystrophy does not occur [7, 96]. Currently, CASPAR
includes psoriatic nail dystrophy among the criteria for PsA
[90].
Even when PsA appears likely, differential diagnosis of
PsA versus other arthritic and rheumatologic conditions
should be considered [8, 74, 76, 97]. This can be chal-
lenging, given the many overlapping clinical features
among these conditions (Table 1) [8, 73–81]. Hallmark
clinical features differentiating PsA from other, similar
arthropathies include the presence of psoriatic skin
involvement in nearly all cases, nail dystrophy and dacty-
litis. Diagnostic laboratory markers for PsA are lacking,
and those used to date have typically helped differentiate
PsA from other conditions rather than specifically diag-
nosing PsA [98]. Evaluation of the erythrocyte sedimen-
tation rate and C-reactive protein level has limited utility in
diagnosis of PsA, as these markers have been shown to be
elevated in only about half of the patients with PsA;
however, in PsA patients who do have an elevated eryth-
rocyte sedimentation rate and elevated C-reactive protein
levels, they are useful to assess disease activity and thus
worthwhile to assess in patients who are suspected to have
PsA.
Antibodies to cyclic citrullinated peptides, which are
present in up to 13 % of PsA patients, have also been
evaluated; although their utility in diagnosis is uncertain,
evidence suggests that this marker may be useful in iden-
tifying patients with erosive features and multiple joint
involvement [99]. When evaluating patients with suspected
PsA, imaging studies are important tools. In addition to
radiography, which is the primary method used, ultrasound
has been recommended as an imaging tool to evaluate joint
inflammation in patients with suspected PsA [100].
Assessment tools used by rheumatologists to stage and
treat patients with PsA have been adapted from measures
used in RA and include global assessment questionnaires
and examination of small and large joints, entheses and
digits, including a swollen and tender joint count. An
overall assessment of the skin and nails is also performed
[8, 9, 101, 102]. Adequate assessment of disease severity
and risk of progression is key to making sound treatment
decisions. In clinical trials and registries, baseline PsA
severity and response to treatment are currently gauged by
American College of Rheumatology (ACR) and Disease
Activity Score (DAS) criteria defined for RA on the basis
of tender and swollen joint counts, as well as individual
measures of enthesitis and dactylitis [102]. New PsA-spe-
cific composite indices, which assess varying combinations
of joint involvement, skin involvement, disease activity,
pain, health-related QOL and functional impact—such as
the Composite Disease Activity Index (CPDAI), PsA
Disease Activity Score (PSADAS) and Arithmetic Mean of
Desirability Functions (AMDF)—have recently been
developed, and their psychometric properties are being
evaluated [102, 103]. Risk of disease progression is judged
on the basis of history and initial clinical presentation.
Patients presenting with established PsA for more than
2 years are at relatively greater risk of disease progression
(i.e. clinical damage) than those with a shorter history of
joint involvement [91]. Other recognized predictors of
disease progression are baseline joint damage, baseline
acute-phase reactants, polyarticular presentation and the
number of inflamed joints at each visit [104].
Ideally, dermatologists initiate treatment with a medi-
cation that is effective for both psoriasis and PsA, while
considering proven efficacy in axial disease and clinical
features such as enthesitis and dactylitis. Alternatively,
referral to a rheumatologist for treatment should occur,
especially if the PsA manifestations are not responding
adequately. Recently, the European League Against
Rheumatism (EULAR) established a PsA treatment algo-
rithm (Fig. 3) [89]. This algorithm may serve as a guide for
dermatologists in defining appropriate treatment options
for psoriatic disease to optimally manage these patients,
whether they are treating them alone or in conjunction with
a rheumatologist. The long-term goals of the EULAR
algorithm are to maintain health-related QOL, limit skin
and joint signs and symptoms, and prevent or slow struc-
tural damage [89]. For patients with active PsA, initial
treatment with a traditional disease-modifying anti-rheu-
matic drug (DMARD) should be considered; if the
response is inadequate, an anti-TNF-a biologic agent
should be considered [89] (Table 4 [2, 105–128]).
According to EULAR recommendations, initial treatment
with an anti-TNF-a biologic agent may be prudent for
patients with extensive involvement of skin and joints [89].
The Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) has also published interna-
tional treatment recommendations for PsA [129], which are
currently in the process of being updated. These guidelines
take into account each of the key clinical domains of PsA




Clinical Established inflammatory articular disease
Current psoriasis or history of psoriasis (personal or
family)
Dactylitis (current or history)
Psoriatic nail dystrophy
Radiology Juxta-articular new bone formation
Serology Rheumatoid factor negative
a CASPAR point values: current psoriasis is assigned a score of 2; all
other features are assigned a score of 1. To meet the criteria, patients
must score at least 3 points from the five categories
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EULAR RECOMMENDATIONS FOR THE







Go directly to phase III
Failure phase I:
go to phase II
Failure phase II:
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toxicity in phase I




Adverse prognostic factors b







Predominantly axial disease or
severe enthesitis
Major skin involvement
(also in phase II-IV)
Fig. 3 European League
Against Rheumatism (EULAR)
recommended treatment
algorithm for management of
psoriatic arthritis. The
recommendations have been
divided into four phases. Small
fonts within the ellipses in
phases II and III refer to dose
modifications or an alternative
therapy, as detailed within the
body of the recommendations.
aBecause of the variable nature
of the disease, not all situations
can be covered by this figure;
therefore, it is important to
consult the full text to which the
numbers or letters in
parentheses refer; dotted lines
refer to situations where
deleting a phase is
recommended. bActive disease:
C1 tender and inflamed joint
and/or tender enthesis point,
and/or dactylitic digit, and/or
inflammatory back pain;
adverse prognostic factors: C5
active joints; or high functional
impairment due to activity; or
damage; or past glucocorticoid
use. cThe treatment target is
clinical remission or, if
remission is unlikely to be
achievable, at least low disease
activity; clinical remission is the
absence of signs and symptoms.
Reproduced from Gossec et al.
[89]. Copyright  2012 with
permission from BMJ
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(arthritis, enthesitis, dactylitis, spondylitis and skin disease)
and encourage the clinician to evaluate the patient com-
prehensively in the treatment algorithm, in terms of both
the clinical severity of each domain and the impact on
function and QOL.
4.2 Traditional Treatments
Phototherapy, fumaric acid esters and systemic retinoids
can be effective first-line strategies for psoriasis but do not
improve signs and symptoms of PsA [129]. Non-steroidal
anti-inflammatory drugs (NSAIDs) are first-line treatment
options for mild PsA and may improve joint symptoms [89,
129]. However, NSAIDs are not recommended for treat-
ment of psoriasis, because they may worsen skin lesions
[130–134]. Similarly, traditional regimens of systemic
corticosteroids are not recommended for treatment of
psoriasis, because clinical trial data are not available and
because of their association with psoriasis flares during or
after tapering [129].
4.2.1 Methotrexate
Methotrexate is approved in the USA by the Food and Drug
Administration (FDA) for severe, recalcitrant, disabling
psoriasis and in the UK, Germany, France, Sweden and
Spain for severe psoriasis. European approvals of metho-
trexate for treatment of concomitant psoriasis and PsA are
limited. Although formal clinical evidence is lacking on the
efficacy of methotrexate in PsA, it is commonly used as
first-line therapy and in combination with biologics. Two
randomized, placebo-controlled studies assessed the effi-
cacy and safety of methotrexate in PsA patients; each study
demonstrated significant improvements in global assess-
ment ratings with active treatment [105, 106]. However,
neither study showed a positive effect of methotrexate on
the basis of objective measures such as tender and swollen
joint counts [105, 106]. Methotrexate has not been con-
clusively found to have a positive impact on radiographic
progression seen over 24 months [107]. An observational
cohort study, however, found a mild positive impact of
methotrexate on PsA progression [108].
Comparative studies between methotrexate and other
treatments in psoriasis patients have generally shown
greater efficacy with other treatment options, such as
cyclosporine A [135], adalimumab [136] and briakinumab
[137]. Treatment with methotrexate has been associated
with hepatic, pulmonary and bone marrow toxicity, as well
as teratogenicity [138]. Furthermore, in psoriasis patients
with risk factors for liver disease, such as obesity (fatty
liver) and alcoholism, the potential for transaminase ele-
vation and liver pathology limits long-term use of
methotrexate.
4.2.2 Sulfasalazine
Sulfasalazine is not approved by the FDA for the treatment
of patients with psoriasis or PsA [138]. Although the pre-
cise mechanism of action of sulfasalazine is unknown, it is
thought to have anti-inflammatory effects mediated
through inhibition of the 5-lipoxygenase pathway [139].
Modest improvements in psoriasis have been reported in
randomized, double-blind, controlled studies of sulfasala-
zine [138, 140]. Other studies have demonstrated the
effectiveness of sulfasalazine in PsA [109–111, 141–143],
with short-term data in one small study also showing der-
matologic improvements [110]. The impact of sulfasala-
zine on radiographic progression, however, has not been
reported [109–111, 141–143]. Sulfasalazine has been
associated with gastrointestinal intolerance, arthralgia,
reversible oligospermia, leukopenia and agranulocytosis
[138].
4.2.3 Leflunomide
Leflunomide is a pyrimidine synthesis inhibitor and has
been shown to inhibit T cell activation and proliferation
[144]. It is not approved by the FDA for psoriasis or PsA,
but it is approved by the European Medicines Agency
(EMA) for PsA. In randomized, double-blind, placebo-
controlled studies of patients with both psoriasis and PsA,
leflunomide improved skin and joint symptoms [112–114].
Leflunomide has been associated with gastrointestinal
toxicity (e.g. diarrhoea and nausea), elevated liver
enzymes, increased risk of infections and leukopenia [138].
4.2.4 Cyclosporine A
Cyclosporine A is a potent immunosuppressant and is
thought to act on the immune system at multiple pathways
[145]. It is approved by the FDA for severe, recalcitrant
psoriasis on the basis of positive findings from a number of
controlled clinical trials [138, 146–152]. Three studies
have also demonstrated the safety and modest efficacy of
cyclosporine A in PsA [115–117]. Cyclosporine A has
been associated with nephrotoxicity and hypertension [138]
and is recommended only for short-term use (up to
12 months).
4.2.5 Biologics
4.2.5.1 Anti-TNF-a Agents TNF-a plays a pivotal role in
the chronic inflammation and aberrant immune responses
that underlie psoriasis and PsA. Biologic agents that inhibit
TNF-a, including a fusion protein, etanercept, and anti-
body-based treatments such as infliximab and adalimumab,
are indicated for and have shown efficacy in psoriasis and
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PsA, including inhibition of radiographic progression [2,
118–121, 126, 136, 153–155]. Golimumab, a newer human
monoclonal antibody against TNF-a, is also indicated for
and has shown efficacy in the treatment of PsA on the basis
of positive findings from a 24-week, randomized, placebo-
controlled study [122] and from open-label extension
studies [123]. Golimumab is not approved by the FDA for
treatment of psoriasis; however, clinical trial evidence
suggests that this agent can have a positive effect on pso-
riatic skin lesions in patients with PsA [122]. Certolizumab
pegol (Cimzia; UCB Pharma, Brussels, Belgium) is a
human anti-TNF-a antibody conjugated with a 40 kDa
polyethylene glycol molecule, which is administered sub-
cutaneously. It is FDA approved for treatment of PsA and
has received a recommendation for marketing authoriza-
tion in Europe by the EMA Committee for Medicinal
Products for Human Use [156, 157]. Because it contains
only a single Fab0 of anti-TNF antibody and lacks an Fc0
portion, certolizumab pegol hypothetically may be less
likely to induce antibody-related complement activation,
apoptosis or cellular toxicity [158]. Results from a ran-
domized, double-blind phase II study of certolizumab pe-
gol showed efficacy in patients with moderate to severe
psoriasis [158]. A phase III, multicentre, double-blind,
parallel-group study in patients with PsA showed
improvement in all PsA clinical domains, including skin
manifestations and physical functioning at week 24 [127,
128]. Twenty percent of the study patients had previously
experienced inadequate responses to an anti-TNF agent
and, despite this, they demonstrated responses similar to
those of the overall study population [127]. Adverse events
were consistent with those seen in other studies of certo-
lizumab pegol.
The evidence surrounding anti-TNF agents and risk
reduction of adverse cardiac events is not definitive. Data
on the cardioprotectiveness of these agents in PsA are not
currently available. A large retrospective Kaiser Perma-
nente Southern California (KPSC) health plan study con-
cluded that TNF inhibitor use in psoriasis was associated
with a significantly reduced myocardial infarction risk,
compared with topical treatment. Although the KPSC data
show promising results, variables in the KPSC study, such
as the use of age as a dichotomous variable in multivariate
analyses and the lack of a longer TNF treatment duration,
raise questions as to whether the use of age as a continuous
variable or a longer study period would have impacted the
findings [159]. Additional studies are needed to further
evaluate the cardioprotective effects of anti-TNF agents in
both psoriasis and PsA.
4.2.5.2 Ustekinumab The anti-IL-12/23 monoclonal
antibody ustekinumab is indicated for and has shown
efficacy in psoriasis [160, 161]. In a phase II study of PsA,
ustekinumab showed improvement in ACR response rates
and significant improvement in skin disease, enthesitis,
dactylitis and physical functioning [124]. The study doses
were higher than those used for managing psoriasis [124,
161]. Similar positive results were recently reported with
ustekinumab in phase III studies in PsA patients who had
previously received anti-TNF and DMARD treatment [162,
Table 4 Traditional disease-modifying anti-rheumatic drugs (DMARDs) and currently available biologics: clinical effects in psoriatic arthritis (PsA)
Drug Evidence for beneficial impact on PsA (? or -)
Signs/symptoms Radiographic damage/
progression
Enthesitis Dactylitis Axial involvement
Methotrexate [105–108] - Inconclusive Unknown Unknown -
Sulfasalazine [109–111] ? - - - -
Leflunomide [112–114] ? Unknown Unknown Unknown -
Cyclosporine A [115–117] ? Unknown Unknown Unknown -
Biologics
Anti-TNF-a antibodies [2] ? ? ? ? Unknowna
Etanercept [125, 126] ? ? ? ? Unknowna
Infliximab [118, 119] ? ? ? ? Unknowna
Adalimumab [120, 121] ? ? Inconclusive Inconclusive Unknowna
Golimumab [122, 123] ? ? ? ? Unknowna
Certolizumab pegol [127, 128] ? ? ? ? Unknowna
Anti-IL-12/23 antibody
Ustekinumab [124, 202] ? ? ? ? Unknown
IL interleukin, TNF tumour necrosis factor
a The efficacy of anti-TNF-a antibodies in axial involvement has not been directly evaluated in PsA trials. Treatment responses reported in
ankylosing spondylitis are used to indicate efficacy in this condition [129]
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163]. Results from the Active Comparator (CNTO1275/
Enbrel) Psoriasis Trial (ACCEPT) in psoriasis demon-
strated that, compared with etanercept treatment, us-
tekinumab treatment resulted in greater improvement in
efficacy parameters at week 12, including achievement of a
75 % improvement in the Psoriasis Area and Severity
Index score (PASI 75; the primary endpoint), a Physician’s
Global Assessment (PGA) score of 0 or 1, and achievement
of a 90 % improvement in the PASI score (PASI 90) [164].
Of note, however, although greater efficacy was seen with
ustekinumab, more than half of the patients in the etaner-
cept group met the primary endpoint, and almost half
obtained a PGA score of 0 or 1 [164].
Direct comparison studies have not yet been conducted
for many of the biologic therapies, which may make it dif-
ficult to determine whether one agent is more beneficial in
treating specific patient symptoms. Overall, TNF agents may
be a better choice than topical treatments when patients have
extensive skin involvement, and the overuse of some topical
agents and associated adverse effects may be of concern
[89]. Guidelines note that efficacy with etanercept may be
lesser or delayed when it comes to PsA skin involvement.
Although there have been no head-to-head comparison
studies with etanercept in PsA, a comparison study in pso-
riasis demonstrated that at 12 weeks, treatment with us-
tekinumab resulted in superior efficacy in skin outcomes,
compared with etanercept. With respect to joint involve-
ment, no evident differences in efficacy have been observed
among the various TNF inhibitors but, again, head-to-head
comparison studies are not available [89]. Although com-
parator studies can provide insight into the efficacy and
safety of an agent in clinical trials, it is always important to
remember the impact that individual patient characteristics
can have on drug performance, thus highlighting the
importance of an individualized approach to drug selection.
Biologics have a number of limitations for patients with
psoriasis and PsA. A substantial proportion of patients with
psoriasis or PsA do not have a sustained response to TNF-a
inhibitors [165, 166]. In addition, some biologics, such as
infliximab, are dosed intravenously, which can be incon-
venient for patients. Loss of response over time, cost and
safety issues affect decisions to use nonbiologic and bio-
logic DMARDs over the long term [167, 168]. An unmet
need exists for an efficacious, well-tolerated, safe and easy-
to-use treatment option for patients with psoriasis and PsA
that improves both skin and joint disease.
4.2.6 Combination Therapy
The available treatment algorithms put forth by the
American Academy of Dermatology (AAD) [101],
GRAPPA [129] and EULAR [89] position combination
therapy with a DMARD/TNF inhibitor or DMARD/other
biologic as treatment for moderate or severe PsA in
patients who still have symptoms after conventional
DMARD use. Minimal literature on the effectiveness of
biologic combination therapy is available, warranting the
need for studies evaluating the combination of two biolo-
gics for PsA [169–173]. The EULAR guidelines further
note that clinical trials to date have not shown superiority
with combination use of TNF inhibitors and synthetic
DMARDs versus TNF inhibitor monotherapy, and addi-
tional trials are needed [89].
5 New and Future Treatment Options
5.1 PDE4 Inhibition
The large PDE enzyme family is the sole route for enzy-
matic degradation of cAMP, an intracellular secondary
messenger, which controls a wide array of cellular func-
tions [174]. Apremilast is an orally available small mole-
cule, which specifically inhibits the activity of PDE4, an
isoform found predominantly in immune cells such as
monocytes, T cells and neutrophils [174]. By inhibiting
PDE4-mediated breakdown of cAMP, apremilast works
intracellularly to regulate inflammatory mediators that are
considered to play an important role in the pathogenesis of
psoriasis and PsA [175, 176].
5.1.1 Apremilast
Phase II studies of apremilast have demonstrated efficacy in
patients with psoriasis and PsA. In one study, apremilast 20
or 30 mg twice daily reduced the severity of moderate to
severe plaque psoriasis over 24 weeks and improved pru-
ritus [177]. In another study, apremilast 20 mg twice daily
or 40 mg once daily improved the signs and symptoms of
PsA over 24 weeks [178]. In both studies, apremilast was
generally well tolerated; the majority ([90 %) of treatment-
related adverse events in the clinical studies were mild to
moderate and did not lead to study discontinuation [177,
178]. The most common treatment-related adverse events
were headache, nausea, diarrhoea, nasopharyngitis, fatigue
and upper respiratory tract infection [177, 178]. No
opportunistic infections were reported [177, 178].
Apremilast is currently being studied in phase III clin-
ical trial programmes for psoriasis and PsA; additional
studies are assessing its efficacy in ankylosing spondylitis,
Behc¸et’s disease and RA. The Efficacy and Safety Trial
Evaluating the Effects of Apremilast in Psoriasis
(ESTEEM) programme is assessing the use of apremilast in
patients with moderate to severe plaque psoriasis in two
52-week, randomized, placebo-controlled trials with long-
term, open-label extensions. Preliminary results from
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ESTEEM 1 have demonstrated the clinical efficacy of
apremilast in significantly reducing the severity of mod-
erate to severe psoriasis and its effectiveness in difficult-to-
treat areas such as the nails and scalp. In addition, apre-
milast was generally well tolerated, with no new safety or
laboratory findings [179, 180]. The Psoriatic Arthritis
Long-term Assessment of Clinical Efficacy (PALACE)
programme is assessing the effects of apremilast on the
signs and symptoms of PsA in four randomized, placebo-
controlled trials with long-term, open-label extensions.
PALACE 3 is evaluating the efficacy and safety of apre-
milast in patients with PsA and a qualifying psoriasis
lesion. Preliminary results from PALACE 1 have con-
firmed the clinical efficacy of apremilast in patients with
PsA who have prior experience with traditional and bio-
logic DMARDs, with no new safety signals and improved
tolerability, compared with the results of phase II studies
[181, 182].
5.2 JAK Inhibitors
Janus kinase (JAK) inhibitors serve as intracellular signal
transduction molecules linked to surface receptors for
multiple pro-inflammatory cytokines, including IL-21,
which are crucial for T cell activation and functioning.
Tofacitinib is a small-molecule inhibitor of JAK1, JAK3
and, to a lesser extent, JAK2, and is administered orally
[183]. Tofacitinib 5 mg twice daily is approved in the USA
for patients with RA who are unresponsive to DMARDs.
With tofacitinib, JAK inhibition may interrupt key com-
ponents of the immune and inflammatory responses that
underlie both psoriasis and PsA. Tofacitinib has shown
efficacy across various parameters in RA [183–185]. The
potential role of tofacitinib in treatment of psoriasis
patients is not yet known; however, in a phase I, random-
ized, controlled, dose-ranging study, tofacitinib was
effective in patients with psoriasis [186]. Similarly, in a
12-week, phase IIb, double-blind, placebo-controlled
study, tofacitinib (2, 5 and 15 mg twice daily) was effec-
tive in treatment of patients with moderate to severe plaque
psoriasis [187]. Decreases in mean neutrophil counts and
haemoglobin values and increases in lipoprotein levels
were observed [187]. Phase III studies with tofacitinib 5
and 10 mg twice daily are ongoing in patients with mod-
erate to severe plaque psoriasis. No clinical efficacy and
safety data for PsA are available but, on the basis of the
results in RA and psoriasis, evaluation of tofacitinib in PsA
is warranted.
5.3 Anti-IL-17 Agents
IL-17 is a pro-inflammatory cytokine involved in the
pathogenesis of psoriasis and PsA, as well as in other
immune-mediated chronic inflammatory disorders. As
such, it has been the object of intense drug development
efforts, and a number of biologic agents targeting this
molecule are being investigated in clinical studies of pso-
riasis and PsA.
5.3.1 Secukinumab
Secukinumab (AIN-457; Novartis Pharmaceuticals Cor-
poration, East Hanover, NJ, USA) is a fully human, tar-
geted monoclonal antibody against IL-17a, and is
administered subcutaneously or intravenously [188, 189].
Preliminary results from phase II studies of secukinumab
have shown efficacy in psoriasis with 150 mg subcutane-
ous regimens, 3 9 75 mg and 3 9 150 mg subcutaneous
doses and 3 mg/kg, 10 mg/kg and 3 9 10 mg/kg intrave-
nous doses [188, 189]. With subcutaneous administration
of secukinumab, the rates of serious adverse events and
infections were comparable to those observed with placebo
[188, 189]. Phase III trials of secukinumab for psoriasis
(ClinicalTrials.gov study identifier NCT01365455) and
PsA (ClinicalTrials.gov study identifier NCT01392326) are
under way. Data are limited on the clinical efficacy and
safety of secukinumab in PsA. A short-term phase II proof-
of-concept study supported a significant phase III pro-
gramme, which is currently under way [190].
5.3.2 Brodalumab
Brodalumab (AMG 827; Amgen, Thousand Oaks, CA,
USA) is a fully human monoclonal antibody, which binds
to the IL-17 receptor and blocks IL-17 signalling [191].
Brodalumab binds with high affinity to human IL-17RA
and blocks the biologic activity of IL-17A, IL-17F, IL-
17A/F heterodimer and IL-17E (IL-25). A phase II study of
subcutaneous brodalumab demonstrated efficacy in patients
with moderate to severe psoriasis [191]. Brodalumab has
also demonstrated efficacy in PsA in a phase II study, with
similar efficacy noted in anti-TNF-experienced and -inex-
perienced patients [192]. Given these positive results,
phase III studies of brodalumab in patients with psoriasis
are under way (ClinicalTrials.gov study identifiers
NCT01708603 and NCT01708629).
5.3.3 Ixekizumab
Ixekizumab (LY2439821; Eli Lilly and Company, India-
napolis, IN, USA) is a humanized anti-IL-17A monoclonal
antibody, which is administered subcutaneously. In a
phase II study, ixekizumab improved clinical symptoms in
patients with moderate to severe psoriasis [193]. Phase III
studies of ixekizumab in psoriasis (ClinicalTrials.gov study
identifier NCT01474512) and PsA (ClinicalTrials.gov
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study identifier NCT01695239) are ongoing; no data are
yet available with this agent in patients with PsA.
5.4 Protein Kinase C Inhibitor
Protein kinase C isoforms are important for activation and
proliferation of T cells, as well as for antigen receptor
function [194]. Activated T cells are considered central to
the psoriatic disease process [194]. Sotrastaurin (AEB071;
Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA) is a protein kinase C inhibitor, which is administered
orally. Sotrastaurin has strong and specific activity on
PKCh, PKCa and PKCb, and lesser activity on PKCd,
PKCe and PKCg [194]. Preliminary phase II proof-of-
concept data suggest its efficacy in psoriasis [194]; addi-
tional phase II study results are expected. No clinical
efficacy and safety data in PsA are available.
5.5 Other Mechanisms
5.5.1 CF101
Adenosine A3 receptors are over-expressed in peripheral
blood mononuclear cells in patients with psoriasis, RA and
Crohn’s disease [195]. CF101 (Can-Fite BioPharma, Petah
Tikva, Israel) is an oral adenosine A3 receptor inhibitor,
which has been shown in preclinical investigations to
decrease production of pro-inflammatory cytokines,
including TNF-a and nuclear factor kappa B (NF-jB), and
to induce inflammatory cell apoptosis, leading to a broad
anti-inflammatory effect [195]. In a phase II, randomized,
double-blind, dose-ranging, placebo-controlled study,
CF101 showed progressive improvement over 12 weeks in
the mean change from baseline in the PASI score, com-
pared with placebo, in patients with plaque psoriasis [195].
Additional investigational treatments for psoriasis and
PsA in phase II studies are summarized in Table 5 [158,
177, 178, 181, 186, 187, 191, 193, 195–200].
6 Conclusions
Psoriatic arthritis is a chronic and progressive inflamma-
tory arthritis closely associated with psoriasis and can lead
to significant morbidity. Dermatologists who treat psoriasis
patients are able to regularly and routinely screen for early
PsA by asking about possible joint pain, stiffness or ten-
derness. Rapid screening questionnaires may also help in
identifying early PsA. In patients with suspected PsA,
dermatologists who are familiar with the distinguishing
clinical features of PsA and the current diagnostic CAS-
PAR can conduct a more thorough evaluation. Depending
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dermatologists may gauge PsA severity and the risk of
progression and initiate treatment. Optimal interventions
for active PsA should aim to control skin and joint signs
and symptoms. For patients with more severe or compli-
cated symptoms, dermatologists and rheumatologists must
collaborate to adequately manage both skin and joint pso-
riatic involvement over the long term.
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